Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis - Association with pulmonary involvement

Clinical and Experimental Rheumatology

Volumn 24, Issue 5, 2006, Pages 508-513

  Dziankowska Bartkowiak, Bozena ^a   Waszczykowska, Elzbieta ^a   Dziankowska Zaboroszczyk, Elzbieta ^a   de Graft Johnson, Jeffrey E ^a   Zalewska, Anna ^a   Łuczyńska, Maria ^a   Nowak, Dariusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Endostatin; Interstitial lung disease; Systemic sclerosis; Vascular endothelial growth factor

Indexed keywords

ALPHA TOCOPHEROL; CYCLOPHOSPHAMIDE; CYTOKINE; ENDOSTATIN; NIFEDIPINE; PREDNISONE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; ENDOSTATINS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845500924     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. FIMIANI C: Systemic sclerosis: a woman's disease. Mod Asp Immunobiol 2001; 1: 233-7.
2. MEDSGER TA: Systemic sclerosis, localized forms of scleroderma and calcinosis. In: McCARTY DJ, KOOPMAN WJ (Eds.) Arthritis and allied conditions: A textbook of rheumatology. Philadelphia: Lea & Febiger 1993; 1253-92.
3. SIMLER NR, BRENCHLEY PE, HORROCKS AW, GREAVES SM, HASLETON PS, EGAN JJ: Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004; 59: 581-5.
4. MEYER KC, CARDONI A, XIANG ZZ: Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med 2000; 135: 332-8.
5. KOYAMA S, SATO E, HANIUDA M, NUMANAMI H, NAGAI S, IZUMI T: Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 382-5.
6. KIKUCHI K, KUBO M, KADONO T, YAZAWA N, IHN H, TAMAKI K: Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139: 1049-51.
7. HEBBAR M, PEYRAT JP, HORNEZ L, HARTON PY, HACHULLA E, DEVULDER B: Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 889-93.
8. DISTLER O, DEL ROSSO A, GIACOMELLI R et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11.
9. Subcommittee for scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
10. LEROY EC, BLACK CM, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
11. SILVER RM, MILLER SK: Lung involvement in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 199-216.
12. STUPI AM, STEEN VD, OWENS GR et al.: Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
13. American Thoracic Society: Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
14. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 Update. Am J Respir Crit Care Med 1995; 152: 2185-98.
15. QUANJER PH, TAMMELING GJ, COTES JE, PEDERSEN OF, PESLIN R, YERNAULT JC: Lung volumes and forced ventilatory flows. Report working party standardization of lung European Respiratory Society. Eur Respir J 1993; 6 (Suppl. 16): 5-40.
16. LUCZYŃSKA M, SZKUDLAREK U, DZIANKOWSKA-BARTKOWIAK B et al.: Elevated whole blood chemiluminescence in patients with systemic sclerosis. Clin Exp Rheumatol 2005, 23, 173-9.
17. ALLANORE Y, BORDERIE D, LEMARECHAL H, EKINDJIAN OG, KAHAN A: Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 2004; 6: 309-14.
18. WEN FQ, LIU X, MANDA W et al.: TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol 2003, 111, 1307-18.
19. MELICONI R, PULSATELLI L, DOLZANI P et al.: Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 2000; 43: 2472-80.
20. NAGASHIMA M, ASANO G, YOSHINO S: Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 2000, 27, 2339-42.
21. COLLEONI M, ROCCA A, SANDRI MT et al.: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80.
22. GU JW, GADONSKI G, WANG J, MAKEY I, ADAIR TH: Exercise increases endostatin in circulation of healthy volunteers. BMC Physiol 2004; 16: 4:2.
23. SHAHEEN RM, DAVIS DW, LIU W et al.: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59: 5412-6.
24. LUCZYŃSKA M, SZKUDLAREK U, DZIANKOWSKA-BARTKOWIAK B et al.: Elevated exhalation of hydrogen peroxide in patients with systemic sclerosis. Eur J Clin Invest 2003; 33: 274-9.